CDC head: Much still needs to be done in the battle against Zika | Therapy tested in mice offers hope to children with rare disease | Drug shrinks tumors in disfiguring pediatric disorder
January 4, 2017
FBR Smartbrief
SIGN UP ⋅   FORWARD
Top Story
CDC head: Much still needs to be done in the battle against Zika
CDC Director Thomas Frieden said much work remains in the fight against Zika, including improved diagnostics, vaccine development, mosquito control and studies on Zika's long-term effects on pregnant women, men and infants born to Zika-infected mothers. He said he hopes Congress will approve the proposed $300 million Rapid Reserve Fund that would allow the government to act quickly in the event of an infectious disease emergency.
Reuters (12/30) 
LinkedIn Twitter Facebook Google+ Email
Research Breakthroughs
Therapy tested in mice offers hope to children with rare disease
Therapy tested in mice offers hope to children with rare disease.
(Pixabay)
An experimental therapy tested in mice is now being tested in a few children with Sanfilippo syndrome, a rare and debilitating genetic disorder that affects children. A single dose tested in mice restored enzyme activity, increased life span, and improved cognitive and physiological function.
STAT (12/29) 
LinkedIn Twitter Facebook Google+ Email
 
Drug shrinks tumors in disfiguring pediatric disorder
Oral selumetinib shrank tumors in 17 of 24 children with neurofibromatosis type 1, a genetic condition that causes disfiguring but benign tumors of the peripheral nerves, researchers reported. Previous experiments in mice showed that the drug works by interfering with signaling pathways that regulate tumor growth.
HealthDay News (12/29) 
LinkedIn Twitter Facebook Google+ Email
TRAF6 over-expression studied in mouse blood cells
A study of mice at Cincinnati Children's Hospital Medical Center found that over-expression of the TRAF6 protein in blood cells led to bone marrow failure and impaired formation of blood cells, researchers reported in the journal Nature Immunology. The findings could lead to the development of possible treatment targets for myelodysplasia syndromes, according to the study.
United Press International (12/29) 
LinkedIn Twitter Facebook Google+ Email
Experimental drug shrinks testicular tumors in preclinical studies
An experimental drug developed as a male contraceptive blocks sperm maturation and appears to shrink cancerous testicular tumors. The drug, JQ1, modifies gene expression and prompted apoptosis of tumor cells in mouse models alone and in combination with romidepsin, according to a study in the Journal of Cellular and Molecular Medicine.
United Press International (12/28) 
LinkedIn Twitter Facebook Google+ Email
Other News
Animal Health
Stress might cause dogs to go gray early
A study of 400 dogs found fear of loud sounds and unfamiliar people and animals was associated with gray hair on and around the muzzle. The findings were reported in Applied Animal Behaviour Science.
Daily News (New York) (12/26) 
LinkedIn Twitter Facebook Google+ Email
New drugs offer safer treatment for dogs' itchy skin
One in six dogs has significant itching, and for 15% to 20% of them, atopic dermatitis is the diagnosis. In recent years, veterinarians have started turning to new drugs that offer better results than earlier treatments with fewer side effects.
Pittsburgh Post-Gazette (12/31) 
LinkedIn Twitter Facebook Google+ Email
Policy News
Evidence of effectiveness vital to drug approvals, says FDA head
The standards for clinical trials can be flexible, as in the case of the recently approved Duchenne muscular dystrophy drug, but evidence of effectiveness as well as safety is required by law, said FDA Commissioner Dr. Robert Califf. The FDA's biggest challenges are dealing with the growing complexity of data and the need to make decisions with limited information, he said.
The Washington Post (tiered subscription model) (12/29) 
LinkedIn Twitter Facebook Google+ Email
FBR News
Donate
For 35 years, FBR has advanced biomedical research for the sake of both human and animal health. We can't do our job without your support. Please give what you can. Together we will continue to make a difference.
LinkedIn Twitter Facebook Google+ Email
 
  
  
Making mistakes is the privilege of the active -- of those who can correct their mistakes and put them right.
Ingvar Kamprad,
business magnate
LinkedIn Twitter Facebook Google+ Email
  
  
Learn more about FBR:
About FBR | Donate
About FBR
The Foundation for Biomedical Research (FBR) is the nation’s oldest and largest non-profit dedicated to improving human and animal health by promoting public understanding and support for biomedical research. Our mission is to educate people about the essential role animal research plays in the quest for medical advancements, treatments and cures for both people and animals.
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information